Colorectal Cancer
Capecitabine and Celecoxib w/wo Radiation Therapy for Colorectal Cancer Patients Previously Treated With Fluorouracil (ADAPT - 7707)
A Phase II Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer
Investigator: Edward Lin, MD; Conditions: Recurrent Colon Cancer, Recurrent Rectal Cancer; Status: Recruiting; Study ID: NCT01729923
A Phase III Clinical Trial Evaluating TheraSphere® in Patients with Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy
Investigator: William Harris; Conditions: Colorectal Cancer; Status: Recruiting; Study ID: NCT01483027
Randomised Comparative Study Of Folfox6m Plus SIR-Spheres® Microspheres Versus Folfox6m Alone As First Line Treatment In Patients With Nonresectable Liver Metastases From Primary Colorectal Carcinoma
Investigator: Andrew Coveler, MD; Conditions: Colorectal Cancer, Colorectal Carcinoma, Liver Metastases; Status: Recruiting; Study ID: NCT00724503
A Randomized, Double-Blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab (Avastin), Oxaliplatin, and a Fluoropyrimidine
Investigator: Veena Shankaran; Conditions: Colon Cancer; Gastrointestinal Cancer; Rectal Cancer; Solid Tumors; Status: Recruiting; Study ID: NCT01183780
Statin Polyp Prevention Trial in Patients with Resected Colon Cancer
Investigator: Tanya Wahl, MD; Conditions: Colon Cancer; Status: Recruiting; Study ID: NCT01011478
A Phase 1 Study of ABT-888 (Veliparib) in Combination With Carboplatin (Paraplatin) and Gemcitabline (Gemzar) in Subjects With Advanced Solid Tumors
Investigator: Heidi J. Gray, MD; Conditions: Advanced Solid Tumors; Status: Closed; Study ID: NCT01063816
A Phase 1, Open-label, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects With Selected Advanced or Recurrent Solid Tumors
Investigator: Scott S. Tykodi, MD, PhD; Conditions: Renal Cell Carcinoma, Non-small Cell Lung Cancer, Malignant Melanoma, Epithelial Ovarian Cancer; Status: Recruiting; Study ID: NCT00729664
Validation and Comparison of Biomarkers for the Early Detection of Colorectal Adenocarcinoma
Investigator: William M. Grady, MD; Conditions: Colon Cancer, Rectal Cancer; Status: Recruiting; Study ID: NCT01511653
A Phase 1b/2 Study With Gemcitabine and LY2157299 for Patients With Metastatic Cancer (Phase 1b) and Advanced or Metastatic Unresectable Pancreatic Cancer (Phase 2)
Investigator: Andrew Coveler, MD; Conditions: Neoplasms, Neoplasm Metastasis, Pancreatic Cancer; Status: Recruiting; Study ID: NCT01373164
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Investigator: Andrew Coveler, MD; Conditions: Colorectal Cancer; Status: Recruiting; Study ID: NCT01479465
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Investigator: William P. Harris, MD; Conditions: Colorectal Cancer; Status: Recruiting; Study ID: NCT01478594
A Phase IIA Open Label, Adaptive, Randomized Clinical Trial of Dalotuzumab (MK-0646) Treatment in Combination with Irinotecan Versus Cetuximab and Irinotecan for Patients with Metastatic Rectal Cancers (mRC) Expressing High IGF-1/Low IGF-2 Levels
Investigator: Edward Lin, MD; Conditions: Colon Cancer; Rectal Cancer; Solid Tumors; Status: Recruiting; Study ID: NCT01609231
A Phase II, Multicenter, Open-Label, Randomized Study Evaluating The Efficacy And Safety Of Folfiri + Mehd7945a Versus Folfiri + Cetuximab In Second Line In Patients With Kras Wild-Type Metastatic Colorectal Cancer
Investigator: Andrew Coveler, MD; Conditions: Colorectal Cancer; Status: Recruiting; Study ID: NCT01652482
Join Us On